EBS Technologies (“EBS”) announced today that a clinical study (“Brain functional connectivity network breakdown and restoration in blindness”) published in the highly respected journal Neurology® validates non-invasive brain stimulation for restoring partial vision to an impaired eye. The Company’s NEXT WAVE™ system is a non-invasive brain stimulation device that is designed to expand the visual field of patients with impaired vision caused by glaucoma or stroke or other neurological diseases. NEXT WAVE™ is approved for sale in Europe.
CLICK HERE FOR NEXT WAVE® ANIMATION (ENGLISH)
CLICK HERE FOR NEXT WAVE™ ANIMATION (GERMAN)
“The study confirms that repetitive transorbital alternating current stimulation (rtACS), otherwise known as electrical brain stimulation, can reactivate residual capabilities of brain function,” said Anton Federov, MD, Neurologist, co-author of the study published in Neurology and co-founder of EBS Technologies. “I am delighted that the rtACS-based NEXT WAVE therapy can now be offered to patients at neuroophthalmologic and neurorehabilitation clinics throughout Europe.”
“There is an overwhelming and unmet clinical need for treating vision impairment caused by a variety of ophthalmological and neurological disorders, such as neuropathy of the optic nerve. Indeed, three out of five persons who are disabled from impaired vision as a result of optic nerve neuropathy, for example, or brain injury or stroke, are potentially treatable with our NEXT WAVE™ therapy, which is why we are getting enquiries from patients from not only Europe but also the United States and Asia,” added Ulf Pommerening, CEO of EBS Technologies.
In June 2013, EBS announced the results of a multi-center, 82-patient clinical trial of its NEXT WAVE™ brain stimulation device. About one-half of the clinical trial patients were given a 40-minute treatment protocol for 10 consecutive days with the NEXT WAVE™ device. With an average increase of 24 percent of the total visual field, NEXT WAVE™-treated patients showed significantly better improvements of their total visual field compared with patients in the control group who did not receive NEXT WAVE™ stimulation. All patients had vision impairment lasting at least six months prior to the clinical trial and had exhausted all standard therapeutic options to improve their vision.
Excerpt from the publication Neurology® (2014;83:542-551): “Vision loss in the blind is caused not only by primary tissue damage but also by a breakdown of synchronization in brain networks. Because visual field improvements are associated with resynchronization of alpha band coherence, brain connectivity is a key component in partial blindness and in restoration of vision.”
About NEXT WAVE™
The NEXT WAVE™ technology enables a
unique and patient-centric revitalization of selective communication
paths between neurological cells, which may have been impaired due to
brain injury caused by e.g. trauma, degeneration, tumor resection,
glaucoma or stroke. The non-invasive therapy utilizing the patented NEXT
WAVE™ technology is clinically validated to restore vision
impairment by 20 to 30 percent after optical pathologies. Contact EBS
Technologies for further information: therapy@ebstech.de,
+49 (0) 3302 202 2700
NOTE: NEXT WAVE™ is approved for sale in Europe; it is not approved for sale or investigational use in the U.S.
Contacts:
Ronald Trahan, APR, +1 508-359-4005,
ext. 108
